Last reviewed · How we verify
Aripiprazole; Quetiapine
This is a combination of two atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
This is a combination of two atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Aripiprazole; Quetiapine |
|---|---|
| Sponsor | Taichung Veterans General Hospital |
| Drug class | Atypical antipsychotic combination |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Aripiprazole acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A partial agonist, while quetiapine is a dopamine D2 and serotonin 5-HT2A receptor antagonist. Together, they modulate dopaminergic and serotonergic neurotransmission to treat psychotic disorders and mood disturbances. This combination approach may provide complementary effects for treatment-resistant conditions.
Approved indications
- Schizophrenia
- Bipolar disorder
- Major depressive disorder (adjunctive treatment)
- Treatment-resistant psychosis
Common side effects
- Sedation
- Weight gain
- Akathisia
- Extrapyramidal symptoms
- Orthostatic hypotension
- Metabolic syndrome
- Prolactin elevation
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Enhancing Recovery in Early Schizophrenia (PHASE2)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- National Pregnancy Registry for Psychiatric Medications
- Maternal And Infant Antipsychotic Study
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Measurement of Treatment Effects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole; Quetiapine CI brief — competitive landscape report
- Aripiprazole; Quetiapine updates RSS · CI watch RSS
- Taichung Veterans General Hospital portfolio CI